These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26796641)

  • 1. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19.
    Mallinger A; Schiemann K; Rink C; Stieber F; Calderini M; Crumpler S; Stubbs M; Adeniji-Popoola O; Poeschke O; Busch M; Czodrowski P; Musil D; Schwarz D; Ortiz-Ruiz MJ; Schneider R; Thai C; Valenti M; de Haven Brandon A; Burke R; Workman P; Dale T; Wienke D; Clarke PA; Esdar C; Raynaud FI; Eccles SA; Rohdich F; Blagg J
    J Med Chem; 2016 Feb; 59(3):1078-101. PubMed ID: 26796641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
    Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
    J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
    Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
    Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
    Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
    J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
    Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.
    Johannessen L; Sundberg TB; O'Connell DJ; Kolde R; Berstler J; Billings KJ; Khor B; Seashore-Ludlow B; Fassl A; Russell CN; Latorre IJ; Jiang B; Graham DB; Perez JR; Sicinski P; Phillips AJ; Schreiber SL; Gray NS; Shamji AF; Xavier RJ
    Nat Chem Biol; 2017 Oct; 13(10):1102-1108. PubMed ID: 28805801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
    Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
    J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK8/19 Mediator kinases potentiate induction of transcription by NFκB.
    Chen M; Liang J; Ji H; Yang Z; Altilia S; Hu B; Schronce A; McDermott MSJ; Schools GP; Lim CU; Oliver D; Shtutman MS; Lu T; Stark GR; Porter DC; Broude EV; Roninson IB
    Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10208-10213. PubMed ID: 28855340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer.
    Li Y; Liu Y; Wu J; Liu X; Wang L; Wang J; Yu J; Qi H; Qin L; Ding X; Ren F; Zhavoronkov A
    J Med Chem; 2023 Apr; 66(8):5439-5452. PubMed ID: 37029334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase.
    Mazur M; Bartoszewicz A; Dymek B; Salamon M; Andryianau G; Kowalski M; Olejniczak S; Matyszewski K; Pluta E; Borek B; Stefaniak F; Zagozdzon A; Mazurkiewicz M; Koralewski R; Czestkowski W; Piotrowicz M; Niedziejko P; Gruza MM; Dzwonek K; Golebiowski A; Golab J; Olczak J
    Bioorg Med Chem Lett; 2018 Feb; 28(3):310-314. PubMed ID: 29292229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
    Lapierre JM; Eathiraj S; Vensel D; Liu Y; Bull CO; Cornell-Kennon S; Iimura S; Kelleher EW; Kizer DE; Koerner S; Makhija S; Matsuda A; Moussa M; Namdev N; Savage RE; Szwaya J; Volckova E; Westlund N; Wu H; Schwartz B
    J Med Chem; 2016 Jul; 59(13):6455-69. PubMed ID: 27305487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
    Mallinger A; Crumpler S; Pichowicz M; Waalboer D; Stubbs M; Adeniji-Popoola O; Wood B; Smith E; Thai C; Henley AT; Georgi K; Court W; Hobbs S; Box G; Ortiz-Ruiz MJ; Valenti M; De Haven Brandon A; TePoele R; Leuthner B; Workman P; Aherne W; Poeschke O; Dale T; Wienke D; Esdar C; Rohdich F; Raynaud F; Clarke PA; Eccles SA; Stieber F; Schiemann K; Blagg J
    J Med Chem; 2015 Feb; 58(4):1717-35. PubMed ID: 25680029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.
    Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.